Program: Education Program
Session: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, CMML, Therapies, chemotherapy, Myeloid Malignancies
Session: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, CMML, Therapies, chemotherapy, Myeloid Malignancies
Monday, December 7, 2020, 8:55 AM-9:00 AM
Disclosures: No relevant conflicts of interest to declare.
OffLabel Disclosure: Tipifarnib, Ruxolitinib, Tagraxofusp, Lenzilumab
See more of: Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
See more of: Education Program
See more of: Education Program
Previous Presentation
|
Next Presentation >>